Related Experiment Videos
[Experience in introducing the method of placental therapy in vitiligo in Ukraine]
Likars'Ka Sprava
|July 1, 1995
Insights
Melagenin, derived from human placenta, effectively treated vitiligo in 83% of pediatric patients. This study followed 366 children, assessing treatment for depigmentation over one year.
Area of Science:
- Dermatology
- Pharmacology
- Biochemistry
Context:
- Vitiligo is a chronic skin condition characterized by depigmentation.
- Pediatric vitiligo presents unique challenges in treatment and management.
- Human placenta is a source of bioactive compounds with potential therapeutic applications.
Purpose:
- To evaluate the efficacy and safety of melagenin in treating pediatric vitiligo.
- To determine the optimal usage and patient profile for melagenin therapy.
- To establish indications and contraindications for melagenin treatment in children.
Summary:
- Melagenin, a placental extract promoting melanocyte reproduction and melanin synthesis, was administered to 366 pediatric vitiligo patients (ages 4-15).
- Patients were monitored for one year, with 62 cases exhibiting 71-100% depigmentation.
- Treatment with melagenin demonstrated an 83% efficacy rate in the studied pediatric population.
Impact:
- Melagenin offers a promising therapeutic option for pediatric vitiligo.
- The study provides evidence for the effectiveness of melagenin in repigmentation.
- Established indications and contraindications guide clinical application of melagenin for vitiligo.
Abstract:
The preparation "melagenin" stimulating reproduction of melanocytes and synthesis of melanotic pigment was isolated from human placenta in Cuba. As many as 366 pediatric patients with vitiligo who ranged from 4 to 15 years old were followed up for 1 year. In 62 cases the area of depigmentation amounted to 71 to 100%. Treatment with melagenin proved to be effective in 83% of vitiligo patients. Indications and contraindications have been determined.